当前位置:首页 - 行情中心 - 名臣健康(002919) - 财务分析 - 利润表

名臣健康

(002919)

  

流通市值:70.99亿  总市值:71.51亿
流通股本:2.65亿   总股本:2.67亿

利润表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、营业总收入417,505,779.321,514,450,125.511,078,874,052.86711,668,800.05
  营业收入417,505,779.321,514,450,125.511,078,874,052.86711,668,800.05
二、营业总成本414,286,951.771,495,723,182.311,031,137,681.82673,425,511.37
  营业成本169,292,297.96694,807,506.16503,196,868.03329,242,376.05
  税金及附加1,005,9284,906,861.943,271,680.572,042,234.89
  销售费用204,223,994.86641,220,529.8417,668,460.24267,349,883.84
  管理费用23,549,959.295,710,838.8366,119,377.7846,851,976.38
  研发费用15,078,392.3757,625,371.0840,483,039.4727,805,680.85
  财务费用1,136,379.381,452,074.5398,255.73133,359.36
  其中:利息费用882,983.771,804,851.98873,631.07466,641.42
  其中:利息收入105,777.16655,223.43518,854.47343,491.46
三、其他经营收益
  加:公允价值变动收益179,616.36102,684,755460,242.24309,669.4
  加:投资收益96,350.56342,486.32217,482.72147,972.13
  资产处置收益33,123.39-510,953.34237,163.74233,240.96
  资产减值损失(新)--32,631,301.64-2,863,121.62-267,678.53
  信用减值损失(新)1,109,186.3-35,652,866.81-8,617,104.41-1,809,177.9
  其他收益143,185.211,782,834.551,386,702.34341,247.68
四、营业利润4,780,289.3754,741,897.2838,557,736.0537,198,562.42
  加:营业外收入28.3342,572.5145,195.7237,718.35
  减:营业外支出335,106.021,154,423.84738,235.08578,529.15
五、利润总额4,445,211.6853,630,045.9537,864,696.6936,657,751.62
  减:所得税费用-3,809,836.8525,828,796.83-4,538,555.32-4,399,777.76
六、净利润8,255,048.5327,801,249.1242,403,252.0141,057,529.38
(一)按经营持续性分类
  持续经营净利润8,255,048.5327,801,249.1242,403,252.0141,057,529.38
(二)按所有权归属分类
  归属于母公司股东的净利润9,171,805.4128,308,089.8742,549,813.9541,062,613.12
  少数股东损益-916,756.88-506,840.75-146,561.94-5,083.74
  扣除非经常损益后的净利润9,153,195.01-74,745,563.5441,217,097.2640,763,947.62
七、每股收益
  (一)基本每股收益0.030.110.160.15
  (二)稀释每股收益0.030.110.160.15
九、综合收益总额8,255,048.5327,801,249.1242,403,252.0141,057,529.38
  归属于母公司股东的综合收益总额9,171,805.4128,308,089.8742,549,813.9541,062,613.12
  归属于少数股东的综合收益总额-916,756.88-506,840.75-146,561.94-5,083.74
公告日期2026-04-282026-04-282025-10-292025-08-29
审计意见(境内)标准无保留意见
TOP↑